Maternal inflammation during pregnancy influences fetal immune development and heightens the child’s risk of allergic conditions. Placental inflammation enhances fetal immune memory leading to ...

A medication often prescribed to reduce symptoms among people with lung cancer limits the effectiveness of certain treatments ...

A world-first clinical trial led by Uppsala University Hospital has shown that gene-edited donor islet cells can survive and ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Basel: Novartis has announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Agg-CLNP synergized with abatacept to delay RA-related inflammation and with dexamethasone to prevent flare-ups following ...

It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases.  Read more at ...

Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...